Adverse effects of combination immunotherapy in renal cancer, lung cancer, and melanoma
Onkologie(2022)
Abstract
Imunoterapie se za poslednĂ dekĂĄdu etablovala do terapeutickĂ˝ch algoritmĹŻ mnohĂ˝ch solidnĂch nĂĄdorĹŻ, v Äele s malignĂm melanomem, renĂĄlnĂm karcinomem (RCC) a nemalobunÄÄnĂ˝m karcinomem plic (NSCLC). V souÄasnĂŠ dobÄ je moĹžnĂŠ aplikovat imunoterapii jak v monoterapii, tak v kombinaci s dalĹĄĂm checkpoint inhibitorem. AvĹĄak v pĹĂpadÄ pouĹžitĂ kombinace dvou checkpoint inhibitorĹŻ se dostĂĄvĂĄ do popĹedĂ takĂŠ otĂĄzka rizika vyĹĄĹĄĂho vĂ˝skytu neŞådoucĂch ĂşÄinkĹŻ, pĹedevĹĄĂm v podobÄ tzv. imunitnÄ podmĂnÄnĂ˝ch neŞådoucĂch ĂşÄinkĹŻ (irAE). S ohledem na neustĂĄle se rozĹĄiĹujĂcĂ indikace kombinovanĂŠ imunoterapie v lĂŠÄbÄ solidnĂch tumorĹŻ vyvstĂĄvĂĄ otĂĄzka, zda se mezi sebou jednotlivĂŠ nĂĄdory liĹĄĂ v incidenci a zĂĄvaĹžnosti irAE, coĹž je pĹedmÄtem nĂĄsledujĂcĂho sdÄlenĂ.
MoreTranslated text
Key words
combination immunotherapy,renal cancer,lung cancer
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined